Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 2/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 2/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264673 | 0.91 | P2RY1 (0.35) | P2RY2P2RY1P2RY12 | |
| SCHEMBL264779 | 0.89 | P2RX3 (0.47) | P2RY2P2RY4P2RX3P2RX2P2RX4 | |
| SCHEMBL2610998 | 0.84 | P2RX3 (0.49) | GPR17P2RY2P2RY4P2RX3P2RX2 | |
| SCHEMBL14071995 | 0.84 | P2RY1 (0.41) | GPR17P2RY2P2RX3P2RX2P2RX4 | |
| SCHEMBL280492 | 0.81 | P2RX3 (0.46) | P2RY2P2RX3P2RX2P2RX4P2RY1 | |
| SCHEMBL264655 | 0.79 | ADORA3 (0.40) | — | |
| SCHEMBL264918 | 0.79 | DNPH1 (0.42) | P2RY2P2RX3P2RX4P2RY1P2RX1 | |
| SCHEMBL13877182 | 0.79 | P2RY2 (0.41) | GPR17P2RY2P2RX3P2RX2P2RX4 | |
| SCHEMBL12253589 | 0.77 | P2RY2 (0.44) | GPR17P2RY2P2RY4P2RX3P2RX2 | |
| SCHEMBL14012413 | 0.75 | ADORA3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | GPR17 1585/4885P2RY2 1278/4885P2RY4 1086/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | GPR17 1585/4885P2RY2 1278/4885P2RY4 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.